The approval was based on results from 3 randomized trials which found that Rhopressa was associated with a reduction in intraocular pressure of up to 5mmHg.
"A simple static perimetry approach potentially yields high-quality results in children younger than 10 years," the authors write.
Rhopressa (netarsudil ophthalmic solution) 0.02% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
There were no significant associations between glaucoma and consumption of caffeinated and decaffeinated coffee, iced tea, and soft drinks.
Vyzulta works by metabolizing into two moieties, latanoprost acid, which primarily works within the uveoscleral pathway to increase aqueous humor outflow, and butanediol mononitrate, which releases NO to increase outflow through the trabecular meshwork and Schlemm's canal.
The FDA has completed its initial 60-day review of the New Drug Application (NDA) for Rhopressa (netarsudil; Aerie) 0.02% and determined that it's sufficiently complete to permit a substantive review.
Valeant have re-submitted their NDA for latanoprostene bunod ophthalmic solution after receiving a Complete Response Letter from the FDA last summer.
Allergan announced that the Food and Drug Administration (FDA) has approved the Xen Glaucoma Treatment System for the management of refractory glaucomas, including cases where previous surgical treatment has failed.
Aerie Pharmaceuticals announced topline data from the Mercury 1 study, a Phase 3 trial evaluating the fixed-dose combination product, Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, to lower intraocular pressure (IOP) in patients with glaucoma.
Aerie announced the submission of its New Drug Application (NDA) to the Food and Drug Administration (FDA) for Rhopressa (netarsudil ophthalmic solution) 0.02% to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Latanoprost-eluting contact lenses are effective at lowering intraocular pressure in a glaucoma model, according to an experimental study published online August 29 in Ophthalmology.
A statistically significant variability in the force needed to squeeze a drop from common glaucoma medications was observed in a study published in the Journal of Glaucoma.
Mitomycin C (MMC) and 5-flurouracil (5-FU) improve outcomes following Ahmed glaucoma valve (AGV) implantation, according to a study published online August 4 in Clinical & Experimental Ophthalmology.
Combigan (brimonidine tartrate, timolol maleate; Allergan) ophthalmic solution is now available in a new 15mL bottle size for a 90-day supply.
In a case report published online April 30 in Clinical & Experimental Ophthalmology, venlafaxine-induced increase in intraocular pressure (IOP) is described in a patient with open angle glaucoma.
For patients undergoing toric intraocular lens insertion, visual outcomes are similar for femtosecond laser-assisted cataract surgery (LCS) and phacoemulsification cataract surgery (PCS), according to research published online in Clinical & Experimental Ophthalmology.
Both linked to improvements in visual acuity; only triamcinolone tied to sustained improvement in CMT
Higher dietary nitrate and green leafy vegetable intake is associated with reduced risk of primary open-angle glaucoma (POAG), according to a study published online in JAMA Ophthalmology.
For individuals with and without open-angle glaucoma, intraocular pressure (IOP) increases shortly after starting yoga exercises with head-down positions, according to a study published online in PLOS ONE.
Three newly identified genes associated with primary open angle glaucoma bring the total number of such genes to 15, according to a study published online January 11 in Nature Genetics.
For patients with glaucoma, prostaglandin analogs seem to affect circadian intraocular pressure (IOP)-related patterns, according to a study published in the December issue of Clinical & Experimental Ophthalmology.